Biomarker Discovery and Development


A biomarker can be any kind of molecule indicating the existence, past or present, of living organisms, cellular types, states, and conditions. They are also known as bio-signatures. A biomarker can also be a substance whose detection indicates a particular disease state and/or therapeutic target.  Hence, biomarkers are a much sought after valuable tools for accelerating the development of new medical treatments as they can also serve to identify individuals at greatest risk or who may be suffering a condition they are unaware of.  Once a proposed biomarker has been validated it can be used to diagnose disease risk, determine the presence of disease in an individual, be utilized as a means to measure treatment efficacy, or to tailor treatments for the disease in an individual (choices of drug treatment or administration regimes).


AlfaGene's Approach:

      There is a shortage of well identified biomarkers suitable for the use of new medical treatments as the development process of one is often seen as high risk.  AlfaGene’s  paired cell system of non-transformed epithelial cell lines derived from stem cell-like progenitor cells isolated from both diseased and normal gastrointestinal tissues from the same individual’s body provide a hitherto unattainable stable platform for biomarker discovery in a exact disease specific, organ specific, and cell specific manner with minimal genetic background variability, which can be validated by various genetic and molecular biology methods described herein.


AlfaGene's Research Divisions:

        AlfaGene's research and commercialization efforts are contained within three divisions in order to efficiently maximize research, capitalization, and commercialization efforts with regards to the company's unique technology.  Furthermore, four sub-divisions exist within AlfaGene's Biomarker Discovery and Development Division.